Exagen/$XGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Exagen
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Ticker
$XGN
Sector
Primary listing
Employees
212
Headquarters
Website
Exagen Metrics
BasicAdvanced
$220M
-
-$0.89
1.62
-
Price and volume
Market cap
$220M
Beta
1.62
52-week high
$10.00
52-week low
$2.67
Average daily volume
361K
Financial strength
Current ratio
4.953
Quick ratio
4.304
Long term debt to equity
111.572
Total debt to equity
120.258
Interest coverage (TTM)
-5.03%
Profitability
EBITDA (TTM)
-12.298
Gross margin (TTM)
59.42%
Net profit margin (TTM)
-28.85%
Operating margin (TTM)
-23.85%
Effective tax rate (TTM)
-0.29%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-16.24%
Return on equity (TTM)
-87.94%
Valuation
Price to revenue (TTM)
3.236
Price to book
10.44
Price to tangible book (TTM)
10.44
Price to free cash flow (TTM)
-11.918
Free cash flow yield (TTM)
-8.39%
Free cash flow per share (TTM)
-0.837
Growth
Revenue change (TTM)
3.89%
Earnings per share change (TTM)
-7.96%
3-year revenue growth (CAGR)
11.09%
10-year revenue growth (CAGR)
13.39%
3-year earnings per share growth (CAGR)
-27.17%
10-year earnings per share growth (CAGR)
-45.30%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Exagen stock?
Exagen (XGN) has a market cap of $220M as of August 23, 2025.
What is the P/E ratio for Exagen stock?
The price to earnings (P/E) ratio for Exagen (XGN) stock is 0 as of August 23, 2025.
Does Exagen stock pay dividends?
No, Exagen (XGN) stock does not pay dividends to its shareholders as of August 23, 2025.
When is the next Exagen dividend payment date?
Exagen (XGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Exagen?
Exagen (XGN) has a beta rating of 1.62. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.